A Retrospective Medical Record Review of Utilization Patterns and Medical Resource Use Associated with Repository Corticotropin Injection among Patients with Rheumatologic Diseases in the United States
Tóm tắt
Từ khóa
Tài liệu tham khảo
Acthar HP. Gel (repository corticotropin injection) [prescribing information]. Hazelwood: Mallinckrodt ARD; 2015.
Berkovich R, Agius MA. Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis. Ther Adv Neurol Disord. 2014;7:83–96.
Aggarwal R, Marder G, Loganathan P, et al. Efficacy and safety of adrenocorticotropic hormone gel (Acthar Gel®) in refractory dermatomyositis or polymyositis [ACR/ARHP abstract 2363]. Arthritis Rheumatol. 2015;67(10):2848–9.
Fiechtner JJ, Montroy T. Six months’ treatment of moderately to severely active systemic lupus erythematosus with repository corticotropin injection: an extension of a single-site, open-label trial. J Immunol Clin Res. 2016;3:1025–31.
Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomized, controlled pilot study. Lupus Sci Med. 2016;3:e000180.
Gaylis N, Needell S, Sagliani J. The effect of adrenocorticotropin gel (HP Acthar Gel) in combination with MTX in newly diagnosed RA patients from a clinical and structural perspective. Ann Rheum Dis. 2015;74(2):10661067.
Gillis TM, Crane M, Hinkle C, Wei N. HP Acthar Gel (repository corticotropin injection) as adjunctive therapy in patients with rheumatoid arthritis who have failed at least three biologic therapies with different modes of action. Ann Rheum Dis. 2015;74(2):1066.
Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133–9.
Levine T, Malone J, Efthimiou P, et al. HP Acthar Gel® in dermatomyositis and polymyositis treatment registry: an interim analysis. J Neurol Dis. 2016;4(5):292.
Li X, Golubovsky J, Hui-Yuen J, et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: a retrospective study of patients [version 2]. F1000 Res. 2016;4:1103–14.
Pegram SB. The efficacy and tolerability of H.P. Acthar® Gel (repository corticotropin injection) for the treatment of systemic lupus erythematosus. Ann Rheum Dis. 2015;74(2):1077–8.
Brown AN. Repository corticotropin injection in patients with refractory psoriatic arthritis: a retrospective case series. Open Access Rheumatol. 2016;8:97–102.
Knight T, Bond C, Popelar B, et al. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. Clinicoecon Outcomes Res. 2017;9:271–9.
Wu B, Deshpande G, Gu T, Popelar B, Philbin M. Wan GJ (2017) Demographics, treatment patterns, and healthcare utilization and costs of repository corticotropin injection in patients with systemic lupus erythematosis or rheumatoid arthritis. J Med Econ. 2017;10(1080/13696998):1362411 (Published online August).
Myung G, Nelson WW, McMahon MA (2017) Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J Pharm Technol 2017;33:151–155.
Lupus Research Alliance. Who gets lupus. Lupus Research Alliance website. http://www.lupusny.org/about-lupus/who-gets-lupus . Accessed June 5, 2017
Morgan S, Kennedy J. Prescription drug accessibility and affordability in the United States and abroad. Issue Brief (Commonw Fund). 2010;89:1–12.